Literature DB >> 30144075

Role and translational implication of galectins in arthritis pathophysiology and treatment: A systematic literature review.

Francesca Salamanna1, Francesca Veronesi1, Antonio Frizziero2, Milena Fini3.   

Abstract

Galectins are members of the animal lectin family that bind to the β-galactoside-containing carbohydrate moieties of glycoconjugates. They seem to have an important role in the pathophysiology of several diseases, including arthritis. Osteoarthritis (OA) and rheumatoid arthritis (RA) are chronic conditions with few or no available therapies. In this context, galectins could provide a novel opportunity, but the precise role and mechanism of their involvement in arthritis are still not fully understood. This descriptive systematic literature review summarizes in vitro, in vivo, and clinical studies that analyzed and examined the role and mechanism of action of galectins in arthritis to highlight and clarify their possible translation implication. This review yielded promising evidence that individual galectins, in particular galectin-1, -3, and -9, could play positive or negative roles in the pathogenesis of arthritis, especially in RA and OA. It also emphasized the cell-dependent role of these galectins. This is particularly true for galectin-1, which was shown to have a protective anti-inflammatory role in RA, while it seemed to be associated with cartilage degeneration in OA. In summary, this review underlined that manipulation of certain galectins can suppress or aggravate disease symptoms in arthritis animal models, demonstrating the therapeutic potential of galectins for the treatment of RA and OA. Nevertheless, despite the fact that galectin therapy and therapies acting on galectin expression seem to be an interesting and important opportunity for research, we highlighted that further investigation is necessary to carefully evaluate their potential clinical implications in arthritis.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  arthritis; clinical studies; galectin (Gal); in vitro studies; in vivo studies

Year:  2018        PMID: 30144075     DOI: 10.1002/jcp.27026

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  6 in total

Review 1.  Unraveling How Tumor-Derived Galectins Contribute to Anti-Cancer Immunity Failure.

Authors:  Diego José Laderach; Daniel Compagno
Journal:  Cancers (Basel)       Date:  2021-09-09       Impact factor: 6.575

2.  Boosting the Intra-Articular Efficacy of Low Dose Corticosteroid through a Biopolymeric Matrix: An In Vivo Model of Osteoarthritis.

Authors:  Matilde Tschon; Francesca Salamanna; Lucia Martini; Gianluca Giavaresi; Luca Lorenzini; Laura Calzà; Milena Fini
Journal:  Cells       Date:  2020-06-28       Impact factor: 6.600

3.  Galectin-1, -4, and -7 Were Associated with High Activity of Disease in Patients with Rheumatoid Arthritis.

Authors:  Kamila de Melo Vilar; Michelly Cristiny Pereira; Andrea Tavares Dantas; Moacyr Jesus Barreto de Melo Rêgo; Ivan da Rocha Pitta; Claudia Diniz Lopes Marques; Rafaela Silva Guimarães Gonçalves; Laurindo Ferreira da Rocha Júnior; Ângela Luzia Branco Pinto Duarte; Maira Galdino da Rocha Pitta
Journal:  Autoimmune Dis       Date:  2019-07-22

4.  Galectins-1 and -3 in Human Intervertebral Disc Degeneration: Non-Uniform Distribution Profiles and Activation of Disease Markers Involving NF-κB by Galectin-1.

Authors:  Mahmoud Elshamly; Katharina Kinslechner; Josef G Grohs; Daniela Weinmann; Sonja M Walzer; Reinhard Windhager; Hans-Joachim Gabius; Stefan Toegel
Journal:  J Orthop Res       Date:  2019-06-24       Impact factor: 3.494

5.  The Dysregulated Galectin Network Activates NF-κB to Induce Disease Markers and Matrix Degeneration in 3D Pellet Cultures of Osteoarthritic Chondrocytes.

Authors:  K M Pichler; D Weinmann; S Schmidt; B Kubista; R Lass; L Martelanz; J Alphonsus; R Windhager; H J Gabius; S Toegel
Journal:  Calcif Tissue Int       Date:  2020-11-13       Impact factor: 4.333

6.  Anti-Inflammatory Performance of Lactose-Modified Chitosan and Hyaluronic Acid Mixtures in an In Vitro Macrophage-Mediated Inflammation Osteoarthritis Model.

Authors:  Elena Tarricone; Elena Mattiuzzo; Elisa Belluzzi; Rossella Elia; Andrea Benetti; Rina Venerando; Vincenzo Vindigni; Pietro Ruggieri; Paola Brun
Journal:  Cells       Date:  2020-05-26       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.